UNIQUE

📅 Upcoming

🕒 Recent(90d)

News

• Medicaid will let states use ‘tiers’ to determine medical frailty
  New Medicaid rules use allow use of tiers to determine work exemptions. Advocates fear complex guidelines could cause patients to lose insurance.
  stat · 21h ago
• mRNA cancer vaccines’ biggest barriers to market
  Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
  biopharma_dive · 1d ago
• Epidural Kit Correction: Medical Action Industries Issues Correction for Epidural Kits Containing Spectra Medical Devices Lidocaine Ampules
  Medical Action Industries is correcting epidural kits containing recalled Huons Co. sodium chloride ampules.
  fda_medwatch · 2d ago
• Merck adds 53 to New Jersey chopping block
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
  Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and lea…
  biospace · 2d ago
• Steady stream of crossover rounds stock biotech's IPO pipeline
  Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.
  biospace · 3d ago
• Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
  Solstice Oncology has secured $225 million in series A funding to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.
  fiercebiotech · 3d ago
• Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
  Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s…
  biospace · 3d ago
• Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending
  Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval dec…
  fiercebiotech · 4d ago
• Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
  After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
  biospace · 4d ago